CCR6 and myeloid sarcoma: In early MS patients, CCR6+ and not CCR6- memory or naive CD4+ T cells were highly responsive to myelin peptides [69], suggesting that CCR6 expression demarks CD4+ memory T cells contributing to disease activity (reviewed by Van Langelaar et al., in [70]).